-+ 0.00%
-+ 0.00%
-+ 0.00%
Eisai's subcutaneous formulation of the dementia drug Lecanemab has received approval in Japan.
Share

Please log in to view news

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending